Spinal Stimulation for Chronic Complete Tetraplegia (Complete TESCS)
Primary Purpose
Spinal Cord Injuries
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Therapy with and without spinal cord stimulation
Sponsored by
About this trial
This is an interventional treatment trial for Spinal Cord Injuries
Eligibility Criteria
Inclusion Criteria:
- Willing and able to give informed consent for participation in the study
- Aged ≥18 years
- Injury level C3-C7, American Spinal Cord injury Association Impairment Scale (ASIA) A
- ≥1 year post-injury
- Medically stable, cognitively intact, and able to breathe independently
- Able to attend all sessions two or three times per week, for 2 h sessions and assessments
Exclusion Criteria:
- Any implanted active metallic device including, but not limited to neurostimulators, cochlear implants, pacemakers, implantable defibrillators, or drug delivery pumps
- Possible, suspected, or confirmed pregnancy and/or lactation
- Recent history or fracture, contractures or pressure sore, deep vein thrombosis (DVT) or urinary tract, or other infection that may interfere with the intervention and training
- History of epilepsy and/or seizures
- Severe spasticity which has been unstable over the 3 months prior to enrolment and is not expected to change and/or taking varying doses of anti-spasticity medications which could not be tapered to a stable dose and are not expected to change
- Botulinum toxin injections within 6 months of participation
- Non-injury related neurological impairment
- Clinically significant severe depression in spite of treatment
- Cardiovascular disease
- Autonomic dysreflexia that is severe, ongoing, and has required medical treatment within the past month
- Skin conditions or allergies that may affect electrode placement
- Do not understand English
- Received a stem cell treatment or other treatment that could possibly promote or attenuate neuroplastic changes in spinal or cortical function, within ≥2 years of enrolment; beyond this period, they may be included, provided the treatment was conducted in an accredited facility with proper ethics and regulatory approval.
- Involved in any other study involving stimulation of the spinal cord within 6 months of enrolment
- Information regarding recent rehabilitation or exercise programmes that participants may currently be engaged in will be discussed with clinical staff and fully documented for each participant
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Therapy
Arm Description
Conventional physical therapy will be used with and without spinal cord stimulation to investigate improvement of upper limb function.
Outcomes
Primary Outcome Measures
Acceptance
Whether the treatment protocol is acceptable by people with complete tetraplegia. This will be assessed using semi structured interview results of which will be analysed qualitatively to determine the number of participants who would use the therapy on an ongoing basis.
Secondary Outcome Measures
Clinical effectiveness of spinal cord stimulation using GRASSP tool
Effectiveness of spinal cord stimulation in inducing changes in functional outcome. This will be assessed using the Graded and Redefined Assessment of Strength, Sensibility, and Prehension (GRASSP tool). The unit is based on the GRASSP measurement scale.
Neurophysiological change
Effectiveness of spinal cord stimulation in inducing changes in Neurophysiological equivalence of volitional movement. This will be assessed using changes in amplitude in mV of transcranial magnetic stimulation.
Sensation
Change in sensation due to the intervention. This will be assessed using change the sensory score of the International Standards for Neurological classification of SCI (ISNCSCI)
Spasticity
Changes in upper limb muscle tone using change in the Modified Ashworth Scale.
Autonomic function
Changes in autonomic function will be assessed using changes in the AUTONOMIC STANDARDS ASSESSMENT FORM of the International Spinal Cord Injury Data Set.
Change in perceived health status
The effect of the study on perceived health status of the participants will be assessed using QUALITY OF LIFE BASIC DATA SET of the International Spinal Cord Injury Data Set.
Full Information
NCT ID
NCT05522920
First Posted
August 25, 2022
Last Updated
August 29, 2022
Sponsor
NHS Greater Glasgow and Clyde
Collaborators
International Spinal Research Trust
1. Study Identification
Unique Protocol Identification Number
NCT05522920
Brief Title
Spinal Stimulation for Chronic Complete Tetraplegia
Acronym
Complete TESCS
Official Title
Non-invasive Spinal Cord Stimulation Combined With Activity-based Therapy in Chronic Complete High Level Spinal Cord Injury
Study Type
Interventional
2. Study Status
Record Verification Date
August 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
August 2022 (Anticipated)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NHS Greater Glasgow and Clyde
Collaborators
International Spinal Research Trust
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is investigate the acceptability and effectiveness of transcutaneous spinal cord stimulation in people with complete high level spinal cord injury.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Cord Injuries
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
All participants will receive study intervention
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Therapy
Arm Type
Experimental
Arm Description
Conventional physical therapy will be used with and without spinal cord stimulation to investigate improvement of upper limb function.
Intervention Type
Other
Intervention Name(s)
Therapy with and without spinal cord stimulation
Intervention Description
Conventional therapy only will be followed with conventional therapy combined with electrical spinal cord stimulation.
Primary Outcome Measure Information:
Title
Acceptance
Description
Whether the treatment protocol is acceptable by people with complete tetraplegia. This will be assessed using semi structured interview results of which will be analysed qualitatively to determine the number of participants who would use the therapy on an ongoing basis.
Time Frame
26 weeks at the end of intervention
Secondary Outcome Measure Information:
Title
Clinical effectiveness of spinal cord stimulation using GRASSP tool
Description
Effectiveness of spinal cord stimulation in inducing changes in functional outcome. This will be assessed using the Graded and Redefined Assessment of Strength, Sensibility, and Prehension (GRASSP tool). The unit is based on the GRASSP measurement scale.
Time Frame
26 and 38 weeks, at the end of intervention and at follow up respectively
Title
Neurophysiological change
Description
Effectiveness of spinal cord stimulation in inducing changes in Neurophysiological equivalence of volitional movement. This will be assessed using changes in amplitude in mV of transcranial magnetic stimulation.
Time Frame
26 and 38 weeks, at the end of intervention and at follow up respectively
Title
Sensation
Description
Change in sensation due to the intervention. This will be assessed using change the sensory score of the International Standards for Neurological classification of SCI (ISNCSCI)
Time Frame
26 weeks at the end of intervention
Title
Spasticity
Description
Changes in upper limb muscle tone using change in the Modified Ashworth Scale.
Time Frame
26 weeks at the end of intervention
Title
Autonomic function
Description
Changes in autonomic function will be assessed using changes in the AUTONOMIC STANDARDS ASSESSMENT FORM of the International Spinal Cord Injury Data Set.
Time Frame
26 weeks at the end of intervention
Title
Change in perceived health status
Description
The effect of the study on perceived health status of the participants will be assessed using QUALITY OF LIFE BASIC DATA SET of the International Spinal Cord Injury Data Set.
Time Frame
26 weeks at the end of intervention
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Willing and able to give informed consent for participation in the study
Aged ≥18 years
Injury level C3-C7, American Spinal Cord injury Association Impairment Scale (ASIA) A
≥1 year post-injury
Medically stable, cognitively intact, and able to breathe independently
Able to attend all sessions two or three times per week, for 2 h sessions and assessments
Exclusion Criteria:
Any implanted active metallic device including, but not limited to neurostimulators, cochlear implants, pacemakers, implantable defibrillators, or drug delivery pumps
Possible, suspected, or confirmed pregnancy and/or lactation
Recent history or fracture, contractures or pressure sore, deep vein thrombosis (DVT) or urinary tract, or other infection that may interfere with the intervention and training
History of epilepsy and/or seizures
Severe spasticity which has been unstable over the 3 months prior to enrolment and is not expected to change and/or taking varying doses of anti-spasticity medications which could not be tapered to a stable dose and are not expected to change
Botulinum toxin injections within 6 months of participation
Non-injury related neurological impairment
Clinically significant severe depression in spite of treatment
Cardiovascular disease
Autonomic dysreflexia that is severe, ongoing, and has required medical treatment within the past month
Skin conditions or allergies that may affect electrode placement
Do not understand English
Received a stem cell treatment or other treatment that could possibly promote or attenuate neuroplastic changes in spinal or cortical function, within ≥2 years of enrolment; beyond this period, they may be included, provided the treatment was conducted in an accredited facility with proper ethics and regulatory approval.
Involved in any other study involving stimulation of the spinal cord within 6 months of enrolment
Information regarding recent rehabilitation or exercise programmes that participants may currently be engaged in will be discussed with clinical staff and fully documented for each participant
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mariel Purcell, Consultant
Phone
+44 141 201 2536
Email
margaret.purcell@ggc.scot.nhs.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Bethel C Osuagwu, PhD
Phone
+44 7944142407
Email
bethel.osuagwu@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mariel Purcell, Consultant
Organizational Affiliation
NHS Greater Glasgow and Clyde
Official's Role
Study Director
12. IPD Sharing Statement
Plan to Share IPD
Undecided
IPD Sharing Plan Description
The is no plan yet to share individual participant data.
Learn more about this trial
Spinal Stimulation for Chronic Complete Tetraplegia
We'll reach out to this number within 24 hrs